Cannabis Use Disorder

Clinical picture

• Daily or near-daily use, often beginning on waking, with repeatedly failed cutdown attempts rationalized by the drug's legal status.
• Amotivation, blunted affect, and declining academic or occupational performance are frequent presenting complaints in young adults.
• Withdrawal appears within 1 to 3 days as irritability, anxiety, insomnia, vivid dreams, decreased appetite, sweating, and physical discomfort.
• High-potency concentrates and dabs generate tolerance quickly, so ask about product type and THC percentage rather than frequency alone.
• Cannabinoid hyperemesis presents as cyclic vomiting relieved by hot showers and is frequently misattributed to primary GI disease.
• Acute intoxication brings conjunctival injection, tachycardia, increased appetite, impaired coordination, and distorted time perception.

Criteria snapshot

• Requires at least 2 of 11 criteria within a 12-month period, with severity graded mild 2-3, moderate 4-5, or severe 6 or more.
• Cannabis withdrawal became a formal DSM-5 diagnosis, requiring 3 or more symptoms within about a week of stopping heavy sustained use.
• Craving was added and legal problems were removed, which matters given widespread state-level legalization across the United States.
• Tolerance and withdrawal do not count toward the diagnosis when cannabis is taken under appropriate medical supervision.
• Cannabis-induced psychotic, anxiety, and sleep disorders are coded separately when symptoms exceed expected intoxication effects.

Neurobiology

• THC is a partial agonist at CB1 receptors, which are dense in the hippocampus, cerebellum, basal ganglia, and prefrontal cortex.
• Chronic exposure downregulates CB1 receptors, with substantial receptor recovery documented within roughly 4 weeks of abstinence.
• Indirect mesolimbic dopamine release drives reinforcement, although the magnitude is smaller than that seen with stimulants or opioids.
• Adolescent exposure disrupts endocannabinoid-guided synaptic pruning, correlating with lasting attention, memory, and processing deficits.
• Heavy high-potency use roughly triples psychosis risk in a dose-dependent way, with AKT1 variants and family history moderating susceptibility.
• Heritability runs 50% to 70%, and CNR1 and FAAH variants influence withdrawal severity and the subjective response to intoxication.

Psychology

• Cannabis is commonly used to manage anxiety, insomnia, and boredom, creating negative-reinforcement cycles that worsen the very target symptom.
• Perceived low harm and heavy social normalization delay recognition of impairment and reduce motivation to change use patterns.
• Use suppresses approach to developmental tasks, so functional gains rather than abstinence alone should anchor collaborative treatment goals.
• Peer network and identity effects are strong in adolescence, so family and school involvement outperforms individual work done alone.
• Withdrawal-driven irritability and insomnia in the first two weeks predict relapse, so plan concretely and specifically for that window.

Differential & comorbidity

• Distinguish cannabis-induced psychosis from a primary psychotic disorder, since persistence beyond a month of abstinence favors the latter.
• Anxiety and depressive disorders are frequently both cause and consequence, so reassess the diagnosis after 4 weeks of reduced use.
• Common comorbidities include tobacco and alcohol use disorders, ADHD, PTSD, and other substance use disorders needing parallel treatment.
• Assess driving safety, occupational hazards, and pregnancy exposure, since prenatal cannabis is linked to lower birth weight.
• Screen with the CUDIT-R, and note that synthetic cannabinoid use presents far more severely and requires separate assessment.

Pharmacologic treatment

• No medication is FDA-approved for cannabis use disorder, so structured behavioral treatment remains the foundation of effective care.
• N-acetylcysteine 1200 mg BID showed benefit for abstinence in adolescents but did not replicate in the adult multisite trial.
• Gabapentin 1200 mg/day and dronabinol have modest trial support, mainly reducing withdrawal symptoms rather than actual use.
• Treat comorbidity on its own merits with agents such as sertraline for depression and CBT-I rather than sedatives for insomnia.
• Avoid ongoing benzodiazepines for withdrawal anxiety, since symptoms peak at days 2 to 6 and largely resolve within 2 to 3 weeks.

Psychotherapy

• CBT combined with motivational enhancement therapy over 9 to 12 sessions is the best-supported treatment package for adults.
• Adding contingency management to combined CBT and MET substantially improves abstinence rates during the active treatment phase.
• Multidimensional family therapy and multisystemic therapy lead outcomes for adolescents with cannabis use disorder.
• Brief two-session motivational interventions reduce use among non-treatment-seeking young adults and college student populations.
• Effect sizes are modest and end-of-treatment abstinence approaches only 30%, so frame reduction and function as legitimate goals.

Adjunct options

• Sleep is the leading relapse driver, so deliver CBT-I and set expectations that vivid dreams and insomnia normalize by about week 3.
• Engage school, family, and employer supports for adolescents, since monitoring combined with reinforcement outperforms monitoring alone.
• Apply ASAM criteria for level of care, though most patients are managed in outpatient or intensive outpatient settings.
• Track progress with the CUDIT-R, timeline followback, and creatinine-corrected quantitative urine THC-COOH ratios.
• Counsel on driving impairment lasting several hours and on the sharply greater potency of concentrates, vapes, and edibles.

Clinical pearls

• Cannabis withdrawal is real, peaks at days 2 to 6, and drives most early relapse.
• Ask about THC percentage and product type, not just times used per day.
• Psychosis persisting a month after abstinence points to a primary disorder.